ijms-logo

Journal Browser

Journal Browser

State-of-the-Art Molecular Mechanisms of Pulmonary Pathology in Italy

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".

Deadline for manuscript submissions: closed (30 September 2022) | Viewed by 2095

Special Issue Editor

Special Issue Information

Dear Colleagues,

This Topical Collection aims to provide an up-to-date and comprehensive view of the state of the art of Pulmonary Pathology in Italy.

Based on long-term traditions of fundamental science in Italy, we would like to provide a comprehensive insight into the state of the art of research activities in the country regarding molecular mechanisms of pathogenesis and treatment in pulmonary diseases. All kinds of articles are welcome, including contributions about original investigations in the field as well as reviews. The covered topics of interest include but are not limited to the following:

  • Lung cancer
  • Lung microbiota
  • Lung diseases
  • Lung injury and repair
  • Lung development
  • COPD
  • Pulmonology
  • Lung cancer biomarkers
  • Lung adenocarcinoma
  • Asthma
  • Pulmonary fibrosis
  • Lung infection
  • Bronchiectasis
  • Respiratory diseases
  • Pneumonia
  • Cystic fibrosis

Dr. Patrizia Russo
Collection Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Other

7 pages, 1130 KiB  
Case Report
Oligorecurrent Non-Small-Cell Lung Cancer Treated by Chemo-Radiation Followed by Immunotherapy and Intracranial Radiosurgery: A Case Report and Mini Review of Literature
by Alessio Bruni, Federica Bertolini, Elisa D’Angelo, Giorgia Guaitoli, Jessica Imbrescia, Anna Cappelli, Gabriele Guidi, Alessandro Stefani, Massimo Dominici and Frank Lohr
Int. J. Mol. Sci. 2023, 24(3), 1892; https://doi.org/10.3390/ijms24031892 - 18 Jan 2023
Viewed by 1709
Abstract
Locally advanced non-small-cell lung cancer still represents a “grey zone” in terms of the best treatment choice and optimal clinical outcomes. Indeed, most patients may be suitable to receive different treatments with similar outcomes such as chemo-radiotherapy (CHT-RT) followed by immunotherapy (IO) or [...] Read more.
Locally advanced non-small-cell lung cancer still represents a “grey zone” in terms of the best treatment choice and optimal clinical outcomes. Indeed, most patients may be suitable to receive different treatments with similar outcomes such as chemo-radiotherapy (CHT-RT) followed by immunotherapy (IO) or surgery followed by adjuvant local/systemic therapies. We report a clinical case of a patient submitted to primary thoracic surgery who developed a mediastinal nodal recurrence successfully treated by CHT-RT-IO. Subsequently, a single brain lesion was found to have been successfully treated by single fraction stereotactic ablative radiotherapy. The patient is still on follow-up and she is free from disease having a good quality of life. In this report, we also perform a mini review about the role of CHT-RT followed by IO in treating loco-regional relapse after surgery. The role of SABR after IO is also evaluated, finding that it is safe and well tolerated. More robust and larger clinical data are needed in this particular setting to better define the role of the combination of systemic and local treatments in the management of intrathoracic and intracranial relapse for patients already submitted to CHT-RT followed by immunotherapy. Full article
(This article belongs to the Special Issue State-of-the-Art Molecular Mechanisms of Pulmonary Pathology in Italy)
Show Figures

Figure 1

Back to TopTop